Myriad Genetic (NASDAQ:MYGN) and Illumina (NASDAQ:ILMN) announce the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) ...

BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...

Myriad Genetics, Inc. MYGN recently announced the expansion of a strategic partnership with Illumina Inc. ILMN to widen access to oncology homologous recombination deficiency (HRD) testing in the ...

Tesaro has made a deal with Myriad Genetics to use Myriad's homologous recombination deficiency (HRD) test to look for tumor types that may respond to its poly-ADP ribose polymerase (PARP) inhibitor, ...

Homologous recombination repair deficiency (HRD) is associated with response to poly-ADP-ribose polymerase inhibition (PARPi) therapy in advanced ovarian cancer. In combination with CGP, these ...

A community-based study found that despite current guidelines recommending that all patients diagnosed with epithelial ovarian cancer undergo testing for homologous repair deficiency (HRD), only about ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...

The Association for Molecular Pathology announced the publication of best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency (HRD) testing ...

B-Cell–Mediated Immunity Predicts Survival of Patients With Estrogen Receptor–Positive Breast Cancer To meet the urgent need for accessible homologous recombination-deficient (HRD) test options, we ...

The TSO 500 HRD research test aligns Myriad's gold standard MyChoice® CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...